Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Umbralisib in Relapsed/Refractory Solid Tumors
NCT02574663Phase 1Completed
- Sponsor
- TG Therapeutics, Inc.
- Start
- Sep 2015
- Primary completion
- Aug 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of umbralisib in pancreatic cancer (PC), colorectal cancer (CRC), gastric cancer (GC) and 2 more (4 arms), sponsored by TG Therapeutics, Inc. Primary endpoint: Adverse events as a measure of safety and tolerability. Started Sep 2015; status: completed.
02
Drugs
umbralisib
03
Conditions
pancreatic cancer (PC)colorectal cancer (CRC)gastric cancer (GC)esophageal cancergastrointestinal stromal tumor (GIST)
Beyond the preview
Go deeper on NCT02574663.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02574663.